As evidenced in chemoradioresistant nasopharyngeal cancer, salinomycin may inhibit the expression of Nanog protein, in concordance with the results reported in the present study.28 It has been reported that salinomycin entered clinical trials29; however, no outcome of these studies was reported yet. The gene discussed is NANOG; the disease is nasopharyngeal carcinoma.